Aclidinium Dry Powder Inhalation for COPD Physical Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Respiratory patients with severe diseases like COPD experience reduced physical activity, leading to further health deterioration and exacerbation of symptoms, with existing treatments like tiotropium not significantly improving physical activity levels.

Innovation Solution

Aclidinium, a long-acting muscarinic receptor antagonist, is administered as a dry powder via inhalation, preferably using the Genuair device, twice daily, to increase physical activity in respiratory patients by improving bronchodilation and exercise tolerance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tiotropium is administered to COPD patients, then pulmonary function is improved, but physical activity levels are not significantly increased

Engineering Contradiction:

Improvepulmonary functionVSAvoidphysical activity

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the chemical parameter from tiotropium to aclidinium, a different long-acting muscarinic antagonist with improved bronchodilator properties. This parameter change in the pharmaceutical agent results in both maintained pulmonary function and significantly increased physical activity levels in COPD patients

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If physical activity is reduced in severe COPD patients, then respiratory symptoms are exacerbated, but health status deteriorates further

Engineering Contradiction:

Improverespiratory symptomsVSAvoidhealth status

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies preliminary action by administering aclidinium before physical activity reduction occurs, preventing the exacerbation of respiratory symptoms. The drug is given as a maintenance treatment to proactively maintain airway patency and prevent the negative cycle of reduced activity leading to further deterioration

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Aclidinium significantly increases daily physical activity, as measured by steps, moderate activity duration, and active energy expenditure, enhancing the quality of life for respiratory patients without the limitations seen with tiotropium.

Implementation Method 1

Aclidinium, a long-acting muscarinic receptor antagonist, is administered as a dry powder via inhalation

Methodology Applied

Scientific EffectMuscarinic receptor antagonism:

Data Source

PatentEP2931275B1Aclidinium for use in increasing physical activity in daily life in a patient suffering from chronic obstructive pulmonary disease

Publication Date: 2022.06.01 ALMIRALL SA

AI summary

The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the physical activity in respiratory patients.